Method for identification of sensitivity of a patient to telomerase inhibition therapy
US10196677B2 · kind B2 · utility
1Cited by
28References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2017 |
| Grant date | Feb 5, 2019 |
| Priority date | — |
| Expiry date | Feb 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.